NCT00432562View on ClinicalTrials.gov

A Bioequivalence Study of Vinorelbine Tartrate Injectable Emulsion in Patients With Advanced Cancer.

PHASE1CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

February 28, 2007

Primary Completion Date

November 30, 2007

Study Completion Date

December 31, 2007

Conditions
Breast CancerNon-small Cell Lung CancerNon-Hodgkins Lymphoma
Interventions
DRUG

Vinorelbine Tartrate

Subjects received one dose each of ANX-530 and NAVELBINE, each providing 30 mg/m2 vinorelbine. Study drugs will be infused into an arm vein over ten minutes.

Trial Locations (5)

Unknown

Clinical Investigative Site, Buenos Aires

Clinical Investigative Site, Mendoza

Clinical Investigative Site, Rosario

Clinical Investigative Site, San Miguel de Tucumán

Clinical Investigative Site, Santa Fe

Sponsors

Collaborators (1)

Worldwide Clinical Trials
All Listed Sponsors
collaborator

Synteract, Inc.

INDUSTRY

collaborator

Thywill Latam Solutions SRL

UNKNOWN

collaborator

OCASA Soluciones Logísticas S.A.

UNKNOWN

collaborator

Worldwide Clinical Trials

OTHER

lead

Mast Therapeutics, Inc.

INDUSTRY